Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, May 31, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Evan Seigerman Maintained (VRTX) at Buy with Increased Target to $500 on, May 31st, 2024
Evan Seigerman of BMO Capital, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $480 to $500 on, May 31st, 2024.
Evan has made no other calls on VRTX in the last 4 months.
There are 18 other peers that have a rating on VRTX. Out of the 18 peers that are also analyzing VRTX, 4 agree with Evan's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Brian Abrahams of "RBC Capital" Maintained at Hold with Increased Target to $424 on, Tuesday, May 7th, 2024
- Joseph Stringer of "Needham" Reiterated at Hold on, Tuesday, May 7th, 2024
- William Pickering of "Bernstein" Downgraded from Buy to Hold on, Friday, February 2nd, 2024
- Naz Rahman of "Maxim Group" Downgraded from Strong Buy to Hold on, Wednesday, January 31st, 2024
These are the ratings of the 14 analyists that currently disagree with Evan
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $462 on, Tuesday, May 7th, 2024
- Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $456 on, Tuesday, May 7th, 2024
- Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Increased Target to $450 on, Thursday, April 18th, 2024
- Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $466 on, Wednesday, April 17th, 2024
- Hartaj Singh of "Oppenheimer" Maintained at Buy and Held Target at $500 on, Monday, April 15th, 2024
- Whitney Ijem of "Canaccord Genuity" Maintained at Strong Sell and Held Target at $371 on, Friday, April 12th, 2024
- Liisa Bayko of "Evercore ISI Group" Upgraded from Hold to Buy and Held Target at $438 on, Thursday, April 11th, 2024
- Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $440 on, Tuesday, February 20th, 2024
- Andy Chen of "Wolfe Research" Initiated at Buy on, Thursday, February 15th, 2024
- Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $450 on, Tuesday, February 6th, 2024
- Gena Wang of "Barclays" Maintained at Buy with Increased Target to $472 on, Tuesday, February 6th, 2024
- Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $540 on, Tuesday, February 6th, 2024
- Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $508 on, Wednesday, January 31st, 2024
- Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $559 on, Wednesday, January 31st, 2024
